AUTHOR=Vione Beatrice , Ramacieri Giuseppe , Zavaroni Giacomo , Piano Angela , La Rocca Giorgia , Caracausi Maria , Vitale Lorenza , Piovesan Allison , Gori Caterina , Pirazzoli Gian Luca , Strippoli Pierluigi , Cocchi Guido , Corvaglia Luigi , Locatelli Chiara , Pelleri Maria Chiara , Antonaros Francesca 

TITLE=One-carbon pathway metabolites are altered in the plasma of subjects with Down syndrome: Relation to chromosomal dosage

JOURNAL=Frontiers in Medicine

VOLUME=9

YEAR=2022

URL=https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2022.1006891

DOI=10.3389/fmed.2022.1006891

ISSN=2296-858X

ABSTRACT=<sec><title>Introduction</title><p>Down syndrome (DS) is the most common chromosomal disorder and it is caused by trisomy of chromosome 21 (Hsa21). Subjects with DS show a large heterogeneity of phenotypes and the most constant clinical features present are typical facies and intellectual disability (ID). Several studies demonstrated that trisomy 21 causes an alteration in the metabolic profile, involving among all the one-carbon cycle.</p></sec><sec><title>Methods</title><p>We performed enzyme-linked immunosorbent assays (ELISAs) to identify the concentration of 5 different intermediates of the one-carbon cycle in plasma samples obtained from a total of 164 subjects with DS compared to 54 euploid subjects. We investigated: tetrahydrofolate (THF; DS <italic>n</italic> = 108, control <italic>n</italic> = 41), 5-methyltetrahydrofolate (5-methyl-THF; DS <italic>n</italic> = 140, control <italic>n</italic> = 34), 5-formyltetrahydrofolate (5-formyl-THF; DS <italic>n</italic> = 80, control <italic>n</italic> = 21), S-adenosyl-homocysteine (SAH; DS <italic>n</italic> = 94, control <italic>n</italic> = 20) and S-adenosyl-methionine (SAM; DS <italic>n</italic> = 24, control <italic>n</italic> = 15).</p></sec><sec><title>Results</title><p>Results highlight specific alterations of THF with a median concentration ratio DS/control of 2:3, a decrease of a necessary molecule perfectly consistent with a chromosomal dosage effect. Moreover, SAM and SAH show a ratio DS/control of 1.82:1 and 3.6:1, respectively.</p></sec><sec><title>Discussion</title><p>The relevance of these results for the biology of intelligence and its impairment in trisomy 21 is discussed, leading to the final proposal of 5-methyl-THF as the best candidate for a clinical trial aimed at restoring the dysregulation of one-carbon cycle in trisomy 21, possibly improving cognitive skills of subjects with DS.</p></sec>